Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: AI-700; Imagify; Long retention time synthetic microspheres; Perflubutane Polymer Microspheres

Latest Information Update: 24 Apr 2015

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Massachusetts Institute of Technology
  • Developer Acusphere
  • Class Contrast media; Fluorocarbons; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Coronary disorders

Highest Development Phases

  • No development reported Coronary disorders

Most Recent Events

  • 28 Aug 2014 Development is ongoing in USA
  • 24 Jul 2014 Regulatory submission withdrawn for Coronary disorders (Diagnosis) in European Union (IV)
  • 24 Oct 2012 Preregistration for Coronary disorders (diagnosis) in European Union (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top